Physician profile
Stephen Purdy
NPI 1588951669
$3,147.19
in general payments reported to CMS, 2019-2025
14 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2021: $124 · 2022: $260 · 2023: $796 · 2024: $221 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,356.54 | 2019-2025 | Eysuvis |
| Bausch & Lomb Americas INC. | $316.58 | 2023-2025 | Miebo, Xiidra, Envista Envy Iol |
| Glaukos Corporation | $251.56 | 2023-2025 | Idosetr |
| Oyster Point Pharma, INC. | $226.84 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $201.32 | 2022-2025 | |
| Dompe US, INC. | $145.92 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $135.26 | 2019-2021 | |
| Sight Sciences, INC. | $132.13 | 2022 | |
| Lensar, INC. | $114.10 | 2025 | Lensar Laser System |
| Ocular Therapeutix, INC. | $106.52 | 2023 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.08 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.76 | 2019 | |
| Horizon Therapeutics Plc | $16.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Purdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.